Esther H. Chang

11.9k citations

124 papers · 9.6k indexed · 3 hit papers · h-index 51

Molecular Biology top 1%
Oncology top 0.5%
Genetics top 0.5%
Cancer Research top 1%
Biomaterials top 0.5%

Co-authors: Kathleen F. Pirollo Douglas R. Lowy Edward M. Scolnick Antonina Rait Shiv Srivastava Zhiqiang Zou William A. Blattner Robert A. Weinberg
Topics: RNA Interference and Gene Delivery (35 papers)Cancer-related Molecular Pathways (27 papers)Virus-based gene therapy research (24 papers)
Cited by: Oncology Cancer Research Biomaterials
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States Japan Netherlands

In The Last Decade

Esther H. Chang

124 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of activation of a human oncogene

1982 1.1k citations Esther H. Chang et al. profile →
Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome

1990 930 citations Zhiqiang Zou, Kathleen F. Pirollo et al. profile →
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus

1982 500 citations Esther H. Chang et al. profile →

Peers

Countries citing papers authored by Esther H. Chang

Since Specialization

Citations

This map shows the geographic impact of Esther H. Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther H. Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther H. Chang more than expected).

Fields of papers citing papers by Esther H. Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esther H. Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther H. Chang. The network helps show where Esther H. Chang may publish in the future.

Co-authorship network of co-authors of Esther H. Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Esther H. Chang. A scholar is included among the top collaborators of Esther H. Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esther H. Chang. Esther H. Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SMARCB1 Gene Therapy Using a Novel Tumor-Targeted Nanomedicine Enhances Anti-Cancer Efficacy in a Mouse Model of Atypical Teratoid Rhabdoid Tumors 2024 ·International Journal of Nanomedicine ·Sang Soo Kim,(unknown),Antonina Rait,(unknown),Joe B. Harford,Esther H. Chang	2
2	A tumor‐targeting nanomedicine carrying the p53 gene crosses the blood–brain barrier and enhances anti‐PD‐1 immunotherapy in mouse models of glioblastoma 2019 ·International Journal of Cancer ·Sang Soo Kim,Joe B. Harford,(unknown),(unknown),(unknown),Esther H. Chang	51
3	Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma 2015 ·Cancer Letters ·Sang Soo Kim,Antonina Rait,Eric H. Kim,(unknown),Kathleen F. Pirollo,Esther H. Chang	91
4	Nanomedicine: Past, present and future – A global perspective 2015 ·Biochemical and Biophysical Research Communications ·Esther H. Chang,Joe B. Harford,Michael A. W. Eaton,Patrick Boisseau,Admire Dube,Rose Hayeshi,Hulda Swai,Dong Soo Lee	96
5	T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation 2009 ·Vaccine ·(unknown),You-kyung Choi,Esther H. Chang,Kathleen F. Pirollo,(unknown),Hisayoshi Watanabe,(unknown),A. V. Kachko,K. Krawczyński,Marian Major	26
6	Does a targeting ligand influence nanoparticle tumor localization or uptake? 2008 ·Trends in biotechnology ·Kathleen F. Pirollo,Esther H. Chang	281
7	HER‐2‐Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents 2003 ·Annals of the New York Academy of Sciences ·Antonina Rait,Kathleen F. Pirollo,(unknown),Kevin J. Cullen,Esther H. Chang	26
8	Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer 2001 ·Cancer Gene Therapy ·Antonina Rait,Kathleen F. Pirollo,Vladimir Rait,(unknown),Laiman Xiang,Esther H. Chang	21
9	Tp53 gene therapy: a key to modulating resistance to anticancer therapies? 2000 ·Molecular Medicine Today ·Esther H. Chang,Kathleen F. Pirollo,Kerrie B. Bouker	21
10	Comparative Gene Mapping in the Domestic Cat (Felis catus) 1997 ·Journal of Heredity ·Stephen J. O’Brien,(unknown),Janice S. Martenson,Mary Ann Thompson,William G. Nash,Esther H. Chang,Jennifer A. Marshall Graves,James A. Spencer,(unknown),Hajime Tsujimoto,Leslie A. Lyons	41
11	Evidence Supporting a Signal Transduction Pathway Leading to the Radiation-Resistant Phenotype in Human Tumor Cells 1997 ·Biochemical and Biophysical Research Communications ·Kathleen F. Pirollo,(unknown),Antonina Rait,(unknown),Esther H. Chang	61
12	p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy 1997 ·Oncogene ·Kathleen F. Pirollo,(unknown),Antonina Rait,(unknown),Willard E. Fee,Patricia C. Ryan,Ya‐Wen Chiang,Esther H. Chang	103
13	Expression of the c-erbB-2 (Her-2/neu) Oncoprotein in Human Prostatic Carcinoma 1993 ·The Journal of Urology ·(unknown),(unknown),Isabell A. Sesterhenn,Esther H. Chang,Judd W. Moul	127
14	Oncogenic Basis of Radiation Resistance 1993 ·Advances in cancer research ·Usha N. Kasid,Kathleen F. Pirollo,Anatoly Dritschilo,Esther H. Chang	33
15	Infrequent RAS oncogene mutations in human prostate cancer 1992 ·The Prostate ·Judd W. Moul,Paul Friedrichs,Raymond S. Lance,(unknown),Esther H. Chang	74
16	Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization 1992 ·Genes Chromosomes and Cancer ·Judd W. Moul,(unknown),Esther H. Chang	34
17	Raf Involvement in the Simultaneous Genetic Transfer of the Radioresistant and Transforming Phenotypes 1989 ·International Journal of Radiation Biology ·Kathleen F. Pirollo,(unknown),Song Yuan,Li Li,William A. Blattner,Esther H. Chang	50
18	A fragment of the human c-ki-ras1 pseudogene (HGM9 gene symbol KRASIP), lacalized to 6p12–p11, detects 3 allele, RFLP 1988 ·Nucleic Acids Research ·Hélène Blanché,Esther H. Chang,J Dausset,Howard M. Cann	4
19	Interferon- Induces Altered Oncogene Expression and Terminal Differentiation in A431 Cells 1987 ·Experimental Biology and Medicine ·Esther H. Chang,(unknown),Ronald S. Black,Zhiqiang Zou,(unknown),P. Noguchi,Joe B. Harford	21
20	Assignment of RAS proto-oncogenes in Chinese hamsters: implications for mammalian gene linkage conservation and neoplasia 1986 ·Cytogenetic and Genome Research ·Raymond L. Stallings,Brian D. Crawford,Roberta Black,Esther H. Chang	7

About Esther H. Chang

Esther H. Chang is a scholar working on Biotechnology, Oncology and Virology, having authored 124 papers that have together received 9.6k indexed citations. Recurring topics across this work include RNA Interference and Gene Delivery (35 papers), Cancer-related Molecular Pathways (27 papers) and Virus-based gene therapy research (24 papers). The work is most often cited by research in Oncology (3.1k citations), Cancer Research (1.5k citations) and Biomaterials (1.2k citations). Esther H. Chang has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Kathleen F. Pirollo, Douglas R. Lowy, Edward M. Scolnick, Antonina Rait, Shiv Srivastava, Zhiqiang Zou, William A. Blattner, Robert A. Weinberg, Sang Soo Kim and Mark E. Furth. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact